Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
6.68
Oct 21 • 3:59 PM ET Dollar change+0.26 Percentage change(4.05%)
Aftermarket Close
6.67
Aftermarket • 7:30 PM ET Dollar change-0.01 Percentage change(-0.15%)
Index
RUT
Market Cap
378.48M
Enterprise Value
1.66B
Income
87.50M
Sales
1.02B
Book/sh
-10.81
Cash/sh
3.85
Employees
1850
IPO
Mar 22, 2022
P/E
4.50
Forward P/E
3.79
PEG
-
P/S
0.37
P/B
-
P/C
1.73
P/FCF
2.30
EV/EBITDA
5.14
EV/Sales
1.63
Quick Ratio
1.17
Current Ratio
1.68
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
1.48
EPS next Y
1.76
EPS next Q
0.29
EPS this Y
-37.76%
EPS next Y
-3.96%
EPS next 5Y
-12.88%
EPS past 3/5Y
-25.52% -
Sales past 3/5Y
-1.47% -0.10%
EPS Y/Y TTM
4.11%
Sales Y/Y TTM
-7.60%
EPS Q/Q
-53.64%
Sales Q/Q
-8.05%
Insider Own
8.24%
Insider Trans
2.38%
Inst Own
85.40%
Inst Trans
-16.32%
ROA
7.22%
ROE
-
ROIC
11.83%
Gross Margin
59.63%
Oper. Margin
26.38%
Profit Margin
8.59%
SMA20
11.44%
SMA50
20.72%
SMA200
0.47%
Trades
Shs Outstand
56.66M
Shs Float
51.99M
52W High
14.91 -55.20%
52W Low
2.77 141.16%
Volatility
4.96% 4.94%
ATR (14)
0.29
RSI (14)
69.89
Beta
0.83
Rel Volume
0.54
Avg Volume
1.30M
Volume
706,720
Perf Week
8.09%
Perf Month
19.50%
Perf Quarter
105.54%
Perf Half Y
-27.47%
Perf YTD
-43.77%
Perf Year
-53.29%
Perf 3Y
-56.90%
Perf 5Y
-
Perf 10Y
-
Prev Close
6.42
Price
6.68
Change %
4.05%
Date Action Analyst Rating Change Price Target Change
May-06-26Downgrade BTIG Research Buy → Neutral
Apr-10-25Initiated Mizuho Neutral $15
Dec-02-24Upgrade Morgan Stanley Underweight → Equal-Weight $13 → $20
Nov-27-24Upgrade BTIG Research Neutral → Buy $26
Oct-20-23Initiated Wolfe Research Peer Perform
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Sep-08-22Initiated BTIG Research Neutral
Aug-01-22Initiated Morgan Stanley Equal-Weight $33
Jun-21-22Initiated BofA Securities Underperform $25
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morris Milton MayoDirectorSep 04 '26Sale5.886,29336,97153,828Sep 08 05:13 PM
Morris Milton MayoDirectorSep 04 '26Proposed Sale5.866,29336,891Sep 04 03:07 PM
Kurdikar DevdattPresident and CEOAug 12 '26Buy4.7030,000140,937804,919Aug 13 10:50 AM
Elguicze JacobSVP and CFOAug 12 '26Buy4.6720,00093,360309,139Aug 13 10:48 AM
Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLOAug 12 '26Buy4.9920,00099,800262,915Aug 13 10:47 AM
HOMBACH ROBERT J.DirectorAug 12 '26Buy4.9745,000223,848109,587Aug 13 10:45 AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
PresidentMr. Devdatt Kurdikar Ph.D.
Senior VP & CFOMr. Jacob P. Elguicze
Senior VPMr. Jeffrey Z. Mann
Senior VP & Chief Human Resources OfficerMs. Jean M. Casner
Senior Vice President of Global Manufacturing & Supply ChainMr. Shaun Curtis